Figure 7.

LKB1 overexpression increases hepatic levels of SIRT1 and FoxO3a in G6pt−/− mice. One-week-old control (+/+) and G6pt−/− (−/−) mice were treated with 2.5 × 10¹¹ pfu/kg of Ad-LKB1 and analyzed at age 3 weeks. (A) Western-blot analyses of hepatic SIRT1, FoxO3a, PPAR-α, PPAR-γ and β-actin in untreated and Ad-LKB1-treated control and G6pt−/− mice (n = 6 for each group). Two sets of representative immune-stained lanes for untreated and Ad-SIRT1-treated control and G6pt−/− mice are shown for each protein. Densitometric quantification was performed and normalized against β-actin. (B) Hepatic levels of triglyceride, glycogen, lactate and G6P in untreated and Ad-LKB1-treated control and G6pt−/− mice (n = 8 for each group). Statistical analyses were performed between control and untreated or Ad-LKB1-treated G6pt−/− mice, and between untreated and Ad-LKB1-treated G6pt−/− mice. Values represent the mean ± SEM. ^*P < 0.05, ^**P < 0.01.